Macitentan (ACT-064992), a Tissue-Targeting Endothelin Receptor Antagonist, Enhances Therapeutic Efficacy of Paclitaxel by Modulating Survival Pathways in Orthotopic Models of Metastatic Human Ovarian Cancer

Potential treatments for ovarian cancers that have become resistant to standard chemotherapies include modulators of tumor cell survival, such as endothelin receptor (ETR) antagonist. We investigated the therapeutic efficacy of the dual ETR antagonist, macitentan, on human ovarian cancer cells, SKOV...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kim, Sun-Jin, Kim, Jang Seong, Kim, Seung Wook, Brantley, Emily, Yun, Seok Joong, He, Junqin, Maya, Marva, Zhang, Fahao, Wu, Qiuyu, Lehembre, François, Regenass, Urs, Fidler, Isaiah J
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press Inc. 2011
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3033595/
https://ncbi.nlm.nih.gov/pubmed/21403842
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados